SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of hip, vertebral and non-vertebral fractures in postmenopausal women with osteoporosis (1-3). Varying doses of denosumab including 30mg/3months have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Aliya Aziz, Alrob, Hajar Abu, M’Hiri, Iman, Said, Hosay, Hussain, Sharjil, Hweija, Ismail, Iqbal, Salman, Davison, Shawn K, Mihai, Romanovschi, Haneef, Hafsa, Qutub, Mona, Zariffeh, Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Bone and Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207611/
http://dx.doi.org/10.1210/jendso/bvaa046.1431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207611/
http://dx.doi.org/10.1210/jendso/bvaa046.1431

Ejemplares similares